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Old age is the greatest risk factor for many diseases, 
including various types of cancer, inflammatory and 
neurodegenerative diseases. Traditional medical science 
combats one disease at a time, instead of combating the 
underlying biological ageing process that leads to many 
age-related diseases. From a whole body system’s point 
of view, this traditional one-disease-at-a-time approach 
focuses  on   the  downstream  diseases,   rather  than  
 
considering the underlying mechanisms of age-related 
functional decline. This approach has limited 
effectiveness at present and is likely to be less effective 
in the future, because of an increasingly larger elderly 
population suffering from multiple age-related diseases. 
In contrast, interventions that slow down ageing and 
promote “healthy ageing” could in principle delay the 
onset of all age-related diseases, with a significant 
benefit to human health and a large reduction of 
healthcare costs [1]. 
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to  increase C. elegans’  lifespan  in  the DGIdb database, where  the effect of  the compounds on an organism’s
lifespan  is unknown.  The  top hit  compounds  can be broadly divided  into  four  groups:  compounds  affecting
mitochondria,  compounds  for  cancer  treatment,  anti‐inflammatories,  and  compounds  for  gonadotropin‐
releasing hormone therapies. 
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Pharmacological interventions are arguably the most 
practical ageing intervention for humans, avoiding the 
main problems with genetic interventions (generally 
unethical in humans) and dietary interventions such as 
caloric restriction, which are difficult to maintain for the 
vast majority of people. For instance, there is currently 
great interest in discovering drugs that mimic the 
process of caloric restriction (caloric restriction 
mimetics) [2,3]. In addition, promising research on 
pharmacological interventions on the ageing process is 
underway at the National Institute of Aging’s 
Intervention Testing Program (ITP), which consists of 
administering drugs or chemical compounds to mice 
under carefully controlled conditions [4,5]. However, as 
mouse experiments are costly and time consuming, so 
far only a limited number of drugs or compounds have 
been evaluated. Thus, using simpler model organisms 
for evaluating a chemical compound’s effect on an 
organism’s lifespan is appealing, and a substantially 
larger number of studies have administered compounds 
to C. elegans than other organisms. As the ITP for mice, 
the Caenorhabditis Intervention Testing Program has 
been introduced for assessing longevity variation for 
chemical compounds [6]. Although C. elegans is 
physiologically different from humans, C. elegans is  
the most studied model organism in ageing research, 
producing insights that are applicable to other 
organisms [7], since cellular-level ageing processes are 
often conserved across distantly-related species [8]. 
According to the GenAge database [9], C. elegans is the 
animal model with by far the most known ageing-
related genes (838 at the time of writing). 
 
In this work we analyse data from the DrugAge 
database [10], which contains information about 
chemical compounds and their effect on the lifespan of 
organisms. DrugAge contains a variety of compounds 
with anti-ageing properties such as gerosuppressant, 
geroprotective and senolytic activity [11–13] as well 
lifespan increasing properties for a specific species. 
Existing databases with lifespan-extending drugs 
include AgeFactDB (http://agefactdb.jenage.de/) [14], 
and Geroprotectors.org [15] (http://geroprotectors.org/). 
DrugAge incorporates data from these resources and 
improves on them by providing a more extensive and 
systematic repertoire of lifespan-extending drugs, 
compounds and substances. DrugAge is manually 
curated and features only information relative to 
lifespan assays conducted in well-controlled studies. 
DrugAge contains data about several model organisms, 
and the majority of compounds in DrugAge have been 
evaluated on C. elegans, so we focus on analysing data 
for this organism.  
 
In order to analyse such data, we use random forests, 
which is a  supervised machine learning method – for a 
recent review of supervised machine learning applied to 
the biology of ageing, see [16]. In this work, the random 
forest builds a classification model to predict whether or 
not a chemical compound will increase the lifespan of 
C. elegans, based on predictive features describing that 
compound. We created datasets with two types of 
predictive features, namely Gene Ontology (GO) terms 
annotated for proteins interacting with the compounds 
and chemical descriptors calculated from each 
compound’s chemical structure. In order to evaluate the 
predictive relevance of these two types of features, we 
created three different datasets: one using as predictive 
features only the GO terms, another using as predictive 
features only the chemical descriptors, and a third 
dataset using both types of features. In addition, the best 
model produced by the random the forest method was 
applied to a screening “external” dataset with com-
pounds from the DGIdb database, where the effect of 
the compounds on an organism’s lifespan is unknown. 
The predictions of that model were used to identify the 
“top hit” compounds in the DGIdb dataset, i.e. 
compounds with higher probabilities of increasing 
lifespan in C. elegans. 
 
There are some related works that performed data 
analysis on compounds increasing C. elegans’ lifespan, 
but without using any predictive machine learning 
method. In particular, Ziehm et al. used an empirical 
scoring function combining several different factors to 
evaluate the relevance of a compound for ageing [17]; 
and Ye et al. (2014) constructed a pharmacological 
network in order to reveal pharmacological classes most 
related to C. elegans’ ageing [18]. In addition, Calvert 
et al. 2016 identified drugs which induce gene 
expression profiles similar to the profiles of genes 
associated with caloric restriction (CR), and observed 
that various genes targeted by lifespan-extending drugs 
are included in CR and longevity networks [3]. 
Furthermore, Aliper et al. [19] utilised computational 
tools to carry out signalling pathway analysis of gene 
expression between young and old stem cells in 
humans. Based on the signalling pathway results, 
known compounds were screened and ranked, in order 
to identify the best compounds to target those pathways 
and restore a “young” cellular profile. A review of 
several specific pharmacological classes extending C. 
elegans’ lifespan can be found in Carretero et al. 2015 
[20], but again with no use of predictive machine 
learning methods. 
 
To the best of our knowledge, this is the first work to 
propose the use of a predictive machine learning 
method (namely Random Forests) to analyse data about 
the effect of chemical compounds in C. elegans’ lifespan, 
as well as the first work to apply machine learning to data 
about compounds in the DrugAge database.  
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RESULTS AND DISCUSSION 
 
Predictive accuracy of the models 
 
We have created a DrugAge dataset specifically for 
studying the classification of compounds into the 
classes “increase lifespan” or “do not increase lifespan”, 
depending on each compound’s effect when administer-
ed to C. elegans. In this dataset, each compound to be 
classified belongs to one of the two just-mentioned 
classes, and is described by a large set of chemical 
descriptors and biological GO term features.  
 
We use the random forest method as the classification 
algorithm to analyse this dataset. This type of method 
was chosen because it is particularly popular in 
bioinformatics [21,22], it is robust to overfitting in 
datasets where the number of features is much larger 
than the number of instances (as with our dataset) 
[22,23], it is relatively simple to understand and to use, 
and finally, in contrast to other state-of-the-art 
classification methods like support vector machines, 
random forests produce interpretable results based on a 
variable (feature) importance measure, an interpretation 
mechanism also exploited in this paper.  
 
Predictive accuracy for the models developed was 
evaluated by Area Under the ROC curve (AUC). This is 
a measure between 0 and 1, with 1 indicating perfect 
(no error) class predictions. The reported predictive 
accuracy used is the median over the 10 test sets of the 
external cross-validation. We report the median 
accuracy, rather than the mean, because the former is 
more robust to outliers. The median AUC results from 
each of the different versions of the DrugAge dataset 
(using either chemical and/or biological descriptors), 
where for each dataset version we optimised the 
parameters ntrees and mtry of the random forest method 

















The AUC results are reported in Table 1. Comparing the 
AUC values across the dataset versions (last column in 
Table 1), it is clear that, in general, the set of chemical 
descriptors have a greater ability to predict a 
compound’s class than the set of GO terms. More 
precisely, the dataset using only chemical descriptors as 
features has substantially larger AUC than the one using 
only GO terms as features (0.781 vs. 0.716, 
respectively). However, the GO term features still offer 
some positive contribution to the predictive accuracy of 
random forests, since the dataset version leading to the 
highest AUC value in Table 1 (0.800) was the one using 
both GO terms and chemical descriptors as features. 
 
Biological and chemical features for the prediction 
of longevity compounds in C. elegans 
  
One of the benefits of utilizing the random forest 
method, as well as it being a highly predictive 
technique, is that for each feature an importance 
measure can be calculated. This importance measure 
(often called variable importance) offers the opportunity 
to interpret the relevance of each feature in the model 
produced. In this work, using the Boruta and Ranger R 
packages [21,24] and computing the importance of 
features in the best model (built using both GO terms 
and chemical descriptors as features), 93 features – 73 
chemical descriptors and 20 GO terms – were selected as 
statistically significant features (full table Supplemental 
Data). Recall that the GO term features are derived from 
the proteins which are targeted by each compound. 
 
The 20 GO terms selected as significant mainly make 
up biological process GO terms (14 out of 20), five 
molecular function terms and one defining a cellular 
component term. Biological process GO terms describe 
a series of processes as well as specific biological 
processes such as macromitophagy and macroautophagy, 






















RF’s optimized parameters 
Median AUC 
ntrees mtry 
GO terms only 300 52 0.716 
Chemical descriptors only 100 16 0.781 
GO terms and chemical descriptors 900 210 0.800 
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in this work. Molecular function GO terms describe 
specific activities that occur at the molecular level such 
as isomerase activity and protein disulfide isomerase 
activity. Finally, cellular component GO terms describe 
locations in the cell, e.g. at the level of organelles or 
macromolecular complexes such as the mitochondrial 
proton-transporting ATP synthase complex, highlighted 
as the only significant cellular component GO term 
feature in this work. 
 
Chemical molecular descriptors are calculated from the 
chemical structure and are normally used to build 
predictive models to study the relationship between a 
compound’s chemical structure and its biological and 
pharmacokinetic properties such as drug distribution and 
absorption [25,26]. This paper is the first use of chemical 
molecular descriptors (as well as GO terms) to study the 
relationship between longevity and the chemical structure 
of compounds that may affect longevity.  
 
Chemical molecular descriptors can be broadly 
categorized into three main groups, which describe a 
compound’s chemical structure and its main properties. 
These groups are: hydrophobic, electronic and steric 
(size and/or shape) descriptors. Hydrophobicity 
descriptors describe the hydrophobic character of a 
chemical compound and how easily it can cross cell 
membranes, and they may also be important for 
receptor interactions. Electronic molecular descriptors 
describe the electron distribution in a chemical 
compound and its electrostatic interactions, therefore 
they give an indication of how strongly (in terms of 
affinity) and how specifically a chemical compound 
binds to specific receptors. Finally, steric descriptors 
describe the size and shape of the chemical compound. 
The size and shape of a compound may influence its 
binding with an enzyme or receptor binding sites and 
can also affect other psychochemical properties. Note 
that a chemical molecular descriptor can belong to more 
than one of the categories described above. 
 
The top 20 selected features with the highest median 
variable importance are shown in Table 2. Considering 
just the top 20 features as shown in Table 2, there are 
slightly more GO terms (12 out of 20) than chemical 
molecular descriptors (8 out of 20). Those 12 GO terms 
include terms related to mitochondrial processes, terms 
related to enzymatic and immunological processes and 
terms related to metabolic and transport processes. 
Furthermore, the eight chemical molecular descriptors 
in the top 20 features contain descriptors related to 
electronic and steric (size and shape) effects, but not to 
hydrophobic effects directly. 
 
It can be seen from the list of important features that the 
vast majority of the most important features are very 
specific molecular and biological processes. However, 
these specific processes are generic in their applicability 
and occur across many tissues and organs. For example 
“isomerase activity” covers a broad range of various 
enzymes that catalyze reactions across many biological 
processes, such as in glycolysis and carbohydrate 
metabolism. Although it is evident that isomerase 
activity is relevant to metabolism (amongst other 
processes) and hence ageing, this feature is not specific 
enough to suggest practical targets for pharmacological 
intervention. In spite of this, some of the specific 
features have been linked with longevity and ageing 
processes.  
 
GO terms related to metabolism encompass the vast 
majority of the GO term features listed in Table 2. 
These GO terms range from very general metabolism-
related properties such as aerobic respiration to more 
specific processes such as dipeptidase activity, pyruvate 
metabolic process, fatty acid transport and mito-
chondrial electron transport from NADH to ubiquinone. 
Given the involvement of metabolic factors in several 
theories of ageing such as the free radical theory of 
ageing, as well as the well-established effect of calorie-
restriction on longevity, it is expectable that the 
compounds that affect ageing do so by interacting with 
these pathways and processes, as evidenced also by the 
importance of such features in the random forest model. 
 
One apparent group of features that can be related to 
longevity and ageing are the GO terms related to 
autophagy (macroautophagy and macromitophagy) and 
mitochondrial processes. Macroautophagy is the process 
where cellular contents are degraded by lysosomes or 
vacuoles and recycled, and this process controls 
cytosolic protein and organelle degradation [27,28]. 
Whereas macromitophagy is the degradation of 
mitochondrion by macroautophagy and controls 
mitochondrial quality and quantity [29]. It is known that 
autophagy in general is associated with ageing 
processes. This can be evidenced by the occurrence of 
degenerative changes in mammalian tissues, similar to 
changes seen with ageing, as a result of genetic 
inhibition of autophagy. Moreover, pharmacological or 
genetic manipulations that increase life span in model 
organisms often stimulate autophagy. In the same way, 
there is a decrease in autophagy with increasing age in 
organisms, which leads to accumulation of damage [30] 
which is thought to be responsible for the functional 
loss in many biological and physiological processes as 
ageing occurs [31,32]. In addition to macroautophagy, 
mitophagy is specifically implicated in ageing. 
Mitophagy has been shown to be a selective, “non-
random” process [33] that is governed by several 
biological pathways (see [34] for a review of the 
molecular mechanisms).  



















































Mitochondrial respiration, and in particular electron 
transport chain, is the main source of reactive oxygen 
species. As a result, mitochondrial homeostasis is 
particularly affected by ageing, as ROS generation in 
mitochondria leads to mitochondrial protein and 



















































regarded as a defense against oxidative stress, 
mitochondrial dysfunction, and ageing. This is 
supported by findings that along with mitochondrial 
biogenesis pathways, a key mediator of mitophagy and 
longevity assurance under conditions of stress in C. 





type Feature Description 
14.4 a_nN MD Number of nitrogen atoms in the molecule 
12.8 isomerase activity GO Catalysis of the geometric or structural changes within one molecule 
11.8 macromitophagy GO Degradation of a mitochondrion by macroautophagy 
11.6 macroautophagy GO Process in which cellular contents are degraded by lysosomes 
11.1 protein disulfide isomerase activity 
GO Catalysis of the rearrangement of both intrachain and 
interchain disulfide bonds in proteins. 
11.0 dipeptidase activity GO Catalysis of the hydrolysis of a dipeptide. 
9.72 pyruvate metabolic process 
GO The chemical reactions and pathways involving 
pyruvate 
9.47 PEOE_VSA+4 MD Total positive van der waals surface area of atoms with atomic charge in the range of 0.20-0.25. 






GO The transfer of electrons from NADH to ubiquinone 
mediated by the multisubunit enzyme known as 
complex I 
8.64 vsurf_Wp2 MD Polar volume at -0.5, a descriptor reflecting the polarizability of a molecule 
8.57 isotype switching GO The switching of activated B cells from IgM biosynthesis to biosynthesis of other isotypes 
8.40 translation GO The cellular metabolic process in which a protein is formed 
8.18 Q_RPC- 
MD Relative negative partial charge, defined as the most 
negative atomic charge divided by the sum of all 
negative atomic charges in the molecule. 
8.09 aerobic respiration GO The enzymatic release of energy from inorganic and organic compounds 
7.98 a_IC 
MD Atom information content (total), defined as the 
entropy of the element distribution in the molecule 
multiplied by the number of atoms. 
7.95 PEOE_VSA_FPPOS 
MD Fractional polar positive vdw surface area 
7.86 triglyceride mobilization 
GO The release of triglycerides from storage within cells or 
tissues, making them available for metabolism. 
7.79 chi1v MD Valence corrected molecular connectivity index (order 1) 
7.70 bpol 
MD Sum of the absolute value of the difference between 
atomic polarizabilities of all bonded atoms in the 
molecule 
GO: Gene ontology term; MD: Chemical Molecular descriptor 
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impaired [35]. It is therefore not unexpected to find in 
this work that chemical compounds that modulated 
mitophagy are also important promoters of longevity. It 
is interesting to note that in model organisms such as C. 
elegans disruption of mitochondrial electron transport 
chain processes can lead to increases in longevity, 
through genetic [36] or pharmacological interventions 
[37]. Finally, a related property, aerobic respiration, was 
also selected by the random forest model. Although 
aerobic respiration is a very broad term encompassing 
many processes that lead to the production of cellular 
energy, it is very well-associated with ageing through 
the known impact of mitochondrial function and caloric 
restriction. 
 
Other GO features with links to longevity and ageing 
processes are protein disulfide isomerase activity and 
translation. Protein disulfide isomerase activity refers to 
the activity of isomerases that are involved in protein 
folding via formation and breakage of disulfide bonds 
within proteins in the endoplasmic reticulum (ER) 
[38,39]. The activity of this enzyme is key to protein 
folding and quality control in the ER. A number of 
studies have demonstrated that the levels of disulfide 
isomerase and their catalytic activity diminish with age 
[40]. Misfolding of proteins and ER stress are alleviated 
by the signalling pathway known as the ER stress 
response or the unfolded protein response, which 
involves protective measures to limit the protein load. 
These include up-regulation of ER chaperones involved 
in the refolding of proteins, activation of pathways 
leading to reduction of protein translation and 
degradation of misfolded proteins. Where ER stress 
cannot be reversed, cellular functions deteriorate and 
apoptosis will occur [41]. There is evidence in the 
literature to suggest that disruption of protein disulfide 
isomerase activity leads to ER stress and accumulation 
of misfolded proteins, which can give rise to age-related 
disease pathology [42]. Finally, the GO term translation 
has a clear biological relevance, since it is well-known 
that translation inhibition extends lifespan in C. elegans 
[43]. Translation has also been highlighted as a prime 
category in age-related genes in C. elegans in a recent 
paper by Fernandes et al. (2016) [44]. It is therefore 
evident that pathways involved in protein translation 
and folding may be a target of anti-ageing compounds, 
hence the significance of GO terms such as 
“translation” and “disulphide isomerase” in the random 
forest model. 
   
The molecular descriptors in Table 2 indicate the 
molecular properties that impact the longevity effect of 
the compounds. From the eight molecular descriptors 
listed in the table, the majority are electrostatic 
descriptors such as PEOE_VSA+4, vsurf_Wp2, 
Q_RPC-, PEOE_VSA_FPPOS and bpol. These 
electrostatic parameters also carry information 
regarding the topology of the molecule, and along with 
steric parameters such as chi1v and a_IC explain the 
interaction and binding of the compounds with their 
target sites. These targets/processes are in addition to 
those already described in the model by the biological 
features (GO terms).  
   
Overall, even though the used dataset (like any other 
biological dataset) is somewhat biased by the fact that 
some genes have been much more studied than others 
[44], some of the most important features shown in 
Table 2 can be related to important and known 
biological processes of ageing and longevity, such as 
those related to autophagy and mitochondrial processes. 
Furthermore, the other selected biological and chemical 
features are a good starting point that warrants further 
investigation, to further link the chemical and biological 
features of chemical compounds with longevity and 
underlying biological ageing processes. 
 
Predictions of novel potential life-extending 
compounds 
 
The best model built from the DrugAge dataset (using 
GO terms and chemical descriptors) was used to predict 
the probability of the class “increase lifespan” for over 
6,000 compounds from the DGIdb database v2 [45], 
where the class label of each compound is unknown. By 
using the predicted class probabilities we can rank and 
prioritise those compounds with the highest probability 
of increasing the lifespan of C. elegans. The list of all 
compounds predicted from the DGIdb dataset and their 
associated class probabilities can be found in the 
Supplemental Data, and the class probabilities for the 
top 20 compounds can be found in Table 3. 
 
As shown in Table 3 the highest predicted class 
probability for a compound in DGIdb was 0.69. 
Although not close to 1, this can be considered a 
relatively high probability, considering that the baseline 
probability (relative frequency) of the class “lifespan 
increase” in the DrugAge dataset used to build the 
model was only 0.20. In this section, we focus on the 50 
“top hit” DGIdb compounds, with the highest values of 
probabilities for the predicted class “lifespan increase”. 
In general, the top hit compounds predicted to have 
longevity enhancing effects fall into four groups: 
compounds affecting mitochondria, compounds used in 
treatments for cancer, anti-inflammatories, and 
compounds used in gonadotropin-releasing hormone 
therapies. 
 
Compounds related to mitochondrial processes 
Acrolein (lifespan increase class probability = 0.69) was 
the top hit in our screening dataset. Acrolein is  a  highly  
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reactive electrophile and a building block to many other 
chemical compounds, including the amino acid 
methionine. This compound has been shown to be an 
electron transport chain inhibitor, leading to 
mitochondrial dysfunction [46]. Acrolein is implicated 
in pathways such as p53 and the NF-κB inflammation 
pathway [47]. Acrolein is toxic at high concentrations 
[46], but at lower doses in vitro exposure to acrolein 
inhibits NF-κB activation, suggesting that inhibition of 
NF-κB gives rise to acrolein’s anti-inflammatory 
properties – however, the evidence is conflicting 
[48,49]. Therefore, the high probability of lifespan 
increase predicted by our model, despite the known 
toxicity of acrolein, may result from the contribution of 
a large diversity of the pathways affected by this 
































Other compounds affecting mitochondrial processes 
include valinomycin and cardiolipin (both with lifespan 
increase class probability = 0.64). Valinomycin is a 
potassium ionophore and causes mitochondrial 
dysfunction by uncoupling oxidative phosphorylation in 
the electron transport chain [50]. Cardiolipin is a 
dimeric phospholipid found in the inner mitochondrial 
membrane (IMM), where it plays a major role in 
oxidative phosphorylation. Alterations in the content 
and composition, and peroxidation of cardiolipin leads 
to mitochondrial dysfunction [51,52]. Decrease in 
cardiolipin content has been observed in ageing brain, 
and in several pathologies including myocardial 
ischemia, heart failure and Parkinson’s disease [53]. 
Therefore, it is expectable that cardiolipin administra-
tion is predicted to promote longevity.  
 
Anti-cancer drugs and longevity 
Anti-cancer compounds from our top 50 hits in the 
DGIdb dataset include drugs such as temsirolimus, 
valspodar and bortezomib. Interestingly, temsirolimus 
(lifespan increase class probability = 0.62) is a 
derivative and pro-drug of sirolimus – also known as 
rapamycin. Rapamycin was the first pharmacological 
compound shown to extend lifespan in both genders in 
mice models [54,55], C. elegans [56] and D. 
melanogaster [57]. Numerous studies indicate that 
inhibition of the TOR (Target of Rapamycin) kinase is 
implicated in lifespan control [58,59]. Temsirolimus 
also inhibits mTOR, and this compound has been shown 
to improve certain cellular phenotypes in accelerated 
ageing models via increasing autophagy [60].  
 
Valspodar (lifespan increase probability = 0.68), the 
second top-hit in our screening dataset, is an 
experimental chemosensitizer drug. Valspodar 
desensitizes tumor cells making them more vulnerable 
to anti-cancer drugs, due to its ability to inhibit P-
glycoprotein (P-gp), which is overexpressed in many 
cancer cells. However, possibly of more relevance is the 
apoptotic effect of valspodar (and its structurally related 
compound, cyclosporine A) that stems from their 
disruption of mitochondrial membrane potential leading 
to mitochondrial dysfunction [61]. 
 
Bortezomib (lifespan increase probability = 0.65) is a 
proteasome inhibitor, and studies have shown that the 
inhibition of proteasome activity by bortezomib is 
associated with enhanced apoptosis due to inhibition of 
NF-κB activity [62,63]. However, this compound also 
leads to the accumulation of misfolded proteins and ER 
stress followed by unfolded protein response (UPR) and 
macroautophagy [64], which may potentially lead to 
longevity promotion.  
 
Dactinomycin (lifespan increase probability = 0.64) 
interferes with ribosome biogenesis through the 
inhibition of RNA polymerase I [65], which leads to the 
activation of p53 [66]. Inhibition of the mTOR pathway 
leads to a reduction of ribosome biogenesis and 
increases lifespan in several species [54,57,67]. mTOR 
and p53 signalling pathways are connected by a number 
of different mechanisms, highlighting a complex 
relationship [66,68,69]. Considering that there are 
similar signaling molecules involved in both cancer and 
Table 3. Top 20 chemical compounds with 
the  highest  lifespan‐increase  class 
























aplyronine a 0.637 
valinomycin 0.637 
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ageing [70,71], such as mTOR [72], p53 [69] and NF-
kB [73], it is not unexpected to find anti-cancer drugs in 
our list of top hit compounds. However, this could be 
due to research bias, where anti-cancer drugs may be 
overrepresented in datasets (including DrugAge) due to 
the extensive study of cancer therapies. 
 
Chemical compounds with anti-inflammageing effects 
Ageing has been characterized by chronic, low-grade 
inflammation, also labeled as “inflammageing” [74]. 
Human studies have shown that suppression of chronic 
inflammation is a major determinant of successful 
longevity, over a very wide age range up to extreme old 
age [75,76].  
 
The compound rdp-58 (lifespan increase class 
probability = 0.67), tested for the treatment of the 
inflammatory disorder ulcerative colitis [77,78], leads to 
a reduction of proinflammatory (tumor necrosis factor 
alpha) TNF-α and interleukins (ILs) such as interferon-
γ, IL-2, IL-6, and IL-12 [79].  
 
Ergotamine (lifespan increase probability = 0.65), a 
vasoconstrictor used for the treatment of migraines, has 
also been shown to reduce the level of proinflammatory 
TNF-α [80]. Dihydroergotamine methanesulfonate 
increases longevity in C.elegans [18] and was used to 
build our models. Dihydroergotamine methanesulfonate 
is a derivative of ergotamine, so this can explain the 
predicted pro-longevity effects for ergotamine. 
 
The compound ro 25-1392 (lifespan increase probability 
= 0.65) is a type II vasoactive intestinal peptide receptor 
(VIPR2) agonist [81]. ro 25-1392 is an analogue of 
vasoactive intestinal peptide (VIP), which binds to both  
VIPR1 and VIPR2, leading to protection in models of 
inflammatory and autoimmune conditions [82,83].  
 
Reproductive hormone factors and longevity 
Gonadotropin-releasing hormone (GnRH) is responsible 
for the release of follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH) in the pituitary gland, 
promoting the production of testosterone and estrogen.  
It is a part of the hypothalamic–pituitary–gonadal axis, 
which helps in the regulation of reproductive and 
immune systems [84]. 
 
In our list of top hit compounds there are examples of 
GnRH antagonists, such as ganirelix [85] and cetrorelix 
[86] (lifespan increase class probabilities 0.67 and 0.66, 
respectively); and agonists such as nafarelin [87] and 
histrelin [88,89] (lifespan increase class probabilities 
0.63 and 0.62, respectively). Both antagonists and 
agonists (whose continued use leads to desensitisation 
of GnRH receptors) of GnRH receptors lead to the 
reduction of FSH and LH.  
The decline in GnRH has been shown to contribute to 
ageing-related changes such as bone fragility and 
reduced neurogenesis in mice. Zhang [90] showed in 
mice that activation of NF-κB in the hypothalamus led 
to a reduced production of GnRH by neurons and that 
continued activation led to accelerated ageing, whereas 
GnRH treatment reduced neurogenesis and decelerated 
ageing. These findings suggest a link between 
inflammation and ageing related to GnRH. However, 
whether this relationship involving GnRH applies to 
humans and primates is questionable, as it appears that 
female primates have higher levels of GnRH with 
increasing age [91], whereas in Norway rats GnRH 
levels decreased with increasing age [92]. It is therefore 
apparent that GnRH has some role in longevity 




In this work we analysed data from the DrugAge 
database [10], which contains information about 
chemical compounds and their effect on the lifespan of 
organisms. We focused on compounds administered to 
C. elegans, since the majority of compounds in 
DrugAge have been evaluated in this model organism. 
For our data analysis, we used the machine learning 
method random forests, which builds a classification 
model to predict whether or not a chemical compound 
will increase the lifespan of C. elegans, based on 
predictive features describing that compound. We built 
three types of classification models, using either 
chemical descriptors or Gene Ontology terms, or both 
types of features. The dataset with both types of features 
led to the highest predictive accuracy in our 
experiments. 
 
We used a score calculated by the random forest 
method to identify the most relevant features. Among 
the 20 highest score features, there are several GO terms 
which have a well-established association with the 
ageing process such as “macromitophagy” and 
“macroautophagy”. The high score of these GO terms is 
consistent with the fact that pharmacological or genetic 
interventions that increase lifespan in model organisms 
often stimulate autophagy [44]. Another example of a 
relevant GO term in the top 20 features was 
“translation”. It is well-known that translation inhibition 
extends lifespan in C. elegans [43]. The interpretation 
of the chemical features in the top 20 features is more 
difficult, since they refer to low-level chemical 
properties rather than broader biological processes – in 
general, those chemical features refer to electronic, size 
and shape effects of the compounds. 
 
Furthermore, we applied the best classification model 
built by the random forest to a screening “external” 
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dataset with compounds from the DGIdb database, 
where the effect of the compounds on an organism’s 
lifespan is unknown. The predictions of that model were 
used to identify the “top hit” compounds in the DGIdb 
dataset, i.e. compounds with higher probabilities of 
increasing lifespan in C. elegans. We observed that 
these top hit compounds can be broadly divided into 
four groups: compounds affecting mitochondria, 
compounds for cancer treatment, anti-inflammatories, 
and compounds for gonadotropin-releasing hormone 
therapies. 
 
In conclusion we have built, using machine learning, a 
model to predict the longevity effects of chemical 
compounds in C.elegans, using the recently published 
DrugAge dataset. The list of top-hit compounds and 
their analysis contributes to our knowledge of likely 
longevity-extending compounds, and experimental 
confirmation of these predictions would be an 






Chemical compounds that increased longevity in C. 
elegans were extracted from the DrugAge database 
(Build 2, release date: 01/09/2016) [10], available from 
the Human Ageing Genomic Resources website [9]. 
These compounds were assigned a positive class label 
(i.e. increased lifespan). Additionally, compounds that 
were found not to increase or had no effect on longevity 
in C. elegans were collected from the literature and 
were assigned a negative class label. The sets of 
positive and negative labelled compounds were 
combined to form the dataset for modelling. For ease, 
hereafter reference to the DrugAge dataset for 
modelling describes the positive entries from DrugAge 
plus the negative class label compounds. The number of 
positive and negative entries obtained were 229 and 
1163 respectively, after dataset curation. The list of 
negative entries is present in the Supplemental Data. 
Compound entries from the DGIdb database v2 [45] 
were used to test and prioritise chemical compounds for 
longevity effects from the classification models built 
from the DrugAge dataset. The DGIdb dataset is used as 
our independent screening (or “external”) dataset, 
where the compounds’ longevity class labels are 
unknown.  
 
Calculation of chemical molecular descriptors for the 
datasets used 
For calculation of chemical molecular descriptors for 
chemical compounds, SMILES (Simplified Molecular-
Input Line-Entry System) codes, which are line 
notations encoding the chemical structure, were 
extracted using PubChem [93] or ChemSpider 
(http://www.chemspider.com). For compounds where 
the chemical structure was not available, the structure 
was drawn directly from the literature reference (if 
available) and the SMILES code extracted. Compounds 
were removed at this stage if there was no SMILES 
code available, contained heavy inorganic metals, were 
duplicate compounds or were compound mixtures. 
Additionally, if there were chemical isomers with the 
same class label, only one entry was kept. For the 
DGIdb dataset, compounds were removed if they had a 
molecular weight greater than 3000 Daltons due to 
software restraints. 
 
For molecular descriptor calculation, MOE (Chemical 
Computing Group Inc.) v2013.0.8 and Advanced 
Chemistry Development ACD Labs/LogD Suite v12 
were used to calculate 2D and 3D molecular descriptors 
using the desalted and minimised chemical structure 
(using the semi-empirical method MOPAC PM6) of 
each compound. For the DrugAge dataset, molecular 
descriptors were removed if they had greater than 98% 
constant values, resulting in a final number of 268 
molecular descriptors. The same 268 molecular 
descriptors were also calculated for the compounds in 
the DGIdb dataset. Due to software limitations, some 
molecular descriptors could not be calculated for some 
compounds. Using the “missForest” R package v1.4 
[94], missing values were imputed for  chemical 
molecular descriptors where this occurred, in both the 
DrugAge and the DGIdb datasets. A total of 1392 
compound entries had molecular descriptors calculated 
for the DrugAge dataset (229 positive and 1163 
negative entries). For the DGIdb dataset, 6802 entries 
had molecular descriptors calculated. 
 
Computation of biological descriptors for the datasets 
used 
Biological descriptors for each compound in each of the 
datasets were obtained by extracting drug-gene 
interactions using the DGIdb v2 database [45] and drug-
protein interactions using the STITCH v4 database [95]. 
For drug-protein interactions using STITCH, only the 
top 100 interactions with a confidence score greater 
than 0.450 (considered a ‘medium confidence strength’ 
in STITCH) were used. The drug–gene/protein inter-
actions obtained were annotated using GO terms 
(biological process, molecular function and cellular 
component terms) using the ClueGO plugin [96] in 
Cytoscape v3.3.0 [97]. For ClueGO, the parameters 
selected were “GO term fusion” and the entire “GO tree 
interval” using a background of Homo sapiens as the 
reference set. Homo sapiens annotations were used 
rather than C. elegans due to the poor representation of 
GO terms for this model organism. There were 10757 
GO terms that were created as categorical biological 
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features for the datasets. For each GO term, for each 
compound a categorical “yes” or “no” feature value was 
provided for each compound, indicating whether or not, 
respectively, the protein interacting with that compound 
was annotated with that GO term. 
 
For this work, classification models were built using 
datasets with different combinations of chemical and 
biological descriptors (features) from the original 
DrugAge dataset. The different datasets used were: 
Firstly, a dataset using only biological descriptors (GO 
terms) as features. Secondly, a dataset using only 
chemical descriptors as features. Thirdly, a dataset 
using both biological and chemical descriptors as 
features. A summary of compound numbers for each of 
the different versions of the DrugAge dataset and the 
DGIdb dataset can be found in Table 4. Datasets 
DrugAge_1 and DrugAge_3 have fewer compounds 
than dataset DrugAge2 because they use GO terms as 
features, and compounds were discarded because their 




In this work we used a random forest algorithm [98]. 
For our classification task, a random forest algorithm 
builds a classification model consisting of a set of 
decision trees, where each tree predicts a class label for 
each new compound. The predictions from all of the 
trees are then counted, and the class label assigned to a 
new compound is the label (positive or negative) with 
the highest number of votes from all of the decision 
trees in the forest. 
 
Random forest training, including parameter 
optimization (explained in more detail below), was 
performed using the “mlr” R package (developer 
version 2.9) [99], which is a general machine learning 

















ing algorithms available in distinct R packages. We 
have trained the random forests that the mlr package 
imported from the “ranger” R package [21]. 
 
After building a random forest model, a measure of 
variable importance can be computed in order to 
identify the most relevant input variables (features) for 
predicting the class variable. We used a permutation-
based method for measuring variable importance. In 
order to evaluate the predictive power of a feature, for 
each tree in the forest, this method computes the 
predictive accuracy of that tree using two versions of 
the data: with random permutation of the values of the 
variable being evaluated, and without random 
permutation (i.e., using the original data). These 
differences of predictive accuracies are averaged over 
all trees in the random forest to give the feature’s 
permutation-based importance value. In this work the 
variable importance values were computed using the 
Boruta R package [21,24] with the unscaled, 
unconditional permutation-based variable importance 
measure [100], performing the analysis on 100 
permutation-based random forests (varying the random 
seed used to generate the permutations).  
 
Measuring predictive accuracy 
 
We use the Area Under the Receiver Operating 
Characteristic Curve (AUC) as the predictive accuracy 
measure in our experiments. This is a popular measure 
of predictive accuracy in both machine learning and 
bioinformatics, and copes well with imbalanced class 
distributions (such as in our datasets). The AUC value 
varies from 0 to 1, with 1 indicating a perfect classifier, 
which would correctly classify every instance; 0.5 
indicating a classifier that randomly guesses the class 
(positive or negative label) for each instance, and 0 
indicating the worst possible classifier, which would 


















Table  4.  Compound  numbers  for  the  DGIdb  dataset  and  different  combinations  of 
DrugAge  datasets using different  combinations of  chemical  and biological descriptors 
used in this work. 
Dataset n Positive n Negative n Total Type of features used 
DrugAge_1 190 783 973 GO terms ONLY 
DrugAge_2 229 1163 1392 Chemical Descriptor ONLY  
DrugAge_3 190 783 973 GO terms + Chemical Descriptors 
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Nested cross-validation and random forest 
parameter optimization 
 
To measure the predictive accuracy of the models 
developed, we used a nested cross-validation procedure. 
First, the DrugAge dataset was randomly divided into 
10 non-overlapping folds with approximately the same 
number of compounds in each fold. The external cross-
validation procedure performs 10 iterations of the 
classification algorithm (random forest), each time 
using one of the folds as the test set and the other 9 
folds as the training set. In each of these 10 external 
cross-validation iterations, an internal 10-fold cross-
validation procedure was applied to the training set. 
That is, the training set was randomly partitioned into 
10 folds of approximately the same size, and 10 
iterations were performed, using one of the training 
folds as a validation set and the other 9 training folds as 
the learning set from which a random forest model is 
built. Hence, in total 100 iterations were performed.  
 
This nested cross-validation structure was used to 
perform parameter optimization in a strict way, using 
only the training set and not the test set in each external 
cross-validation iteration. This is important because 
parameter optimization is part of the training of a 
classification algorithm, and it has to be done using the 
training set only. The test set is reserved purely for 
measuring generalization ability, i.e. the ability to 
correctly predict the classes of compounds not observed 
during training. 
 
A random forest algorithm has two major parameters 
which are often optimized for the target dataset, 
namely: the number of trees in the forest (ntrees) and 
the number of candidate features evaluated to select the 
best feature in each tree node (mtry) [101]. In order to 
optimize these parameters, we tested five settings for 
the ntrees parameter, namely ntrees = 100, 300, 500, 
700, and 900; and three settings for the mtry parameter, 
namely: the square root of the number of features in the 
dataset (the default setting in [23,102]), as well as the 
half and the double of that default setting. For other 
parameters, their default values in the “mlr” R package 
were used. 
 
In the above nested scheme, in each iteration of the 
external cross-validation procedure, parameters are 
optimized as follows: we ran the random forest 
algorithm 15 times, each time with a different 
combination of parameter settings (5 ntrees settings 
times 3 mtry settings), and each time performing an 
internal cross-validation in the training set. The 
parameter setting combination producing the best 
median AUC value across the 10 internal cross-
validation iterations was chosen as the optimized 
parameter settings for the current external cross-
validation iteration, and then a random forest algorithm 
with those optimized parameter settings was ran using 
the entire training set available at the current external 
iteration, with its predictive accuracy being evaluated 
on the test set for that iteration. The final measure of 
predictive accuracy reported in the Results section is the 





We evaluate the results of the random forest in three 
ways. First, we measure its predictive accuracy, using 
the well-known cross-validation procedure that is 
commonly used in supervised machine learning. 
Second, we identify the GO terms most relevant for 
predicting a compound’s effect on C. elegans’ lifespan, 
according to a feature score calculated by the random 
forest, and discuss the relevance of such GO terms to 
the biology of ageing research. Third, we apply the best 
classification model built by the random forest to a 
screening “external” dataset with compounds from the 
DGIdb database, where the effect of the compounds on 
an organism’s lifespan is unknown. That model’s 
predictions are then used to identify the “top hit” 
compounds in the DGIdb dataset which have more 
potential as a pharmacological intervention against 
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